CClinicalTrials.gg
Sign In
RecruitingNCT06166329SIT-EPUpdated Feb 17, 2026

Interest of the Chair Lift Test in the Prognostic Evaluation of Pulmonary Embolism: a Single-center Open Prospective Study

An interventional study of chair lift test in Non-severe Pulmonary Embolism, Pulmonary Embolism and Non-high-risk Pulmonary Embolism, sponsored by University Hospital, Rouen. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by University Hospital, Rouen · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The objective of the study is to evaluate the prognostic performance of the chair lift test in the initial assessment of the severity of non-severe pulmonary embolism in hospitalized patients, in comparison with the current pulmonary embolism risk stratification score using the sPESI score refined by the use of cardiac biomarkers and right ventricular dysfunction

02

Conditions studied

  • Non-severe Pulmonary Embolism
  • Pulmonary Embolism
  • Non-high-risk Pulmonary Embolism
  • Pulmonary Embolism Acute
  • Prognostic Stratification
  • Risk Assessment in Pulmonary Embolism
  • Functional Exercise Testing
  • Early Prognostic Evaluation

Keywords

  • Pulmonary Embolism
  • Prognostic Evaluation
  • Risk Stratification
  • sPESI Score
  • Chair Stand Test
  • One-Minute Sit-to-Stand Test
  • Functional Capacity
  • Right Ventricular Dysfunction
  • Cardiac Biomarkers
  • Troponin
  • NT-proBNP
  • Early Mortality
  • Ambulatory Management
  • Hospitalized Patients
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of pulmonary embolism according to clinical algorithm, confirmed by thoracic angioscan or ventilation perfusion (V/P) scan,
  • Non-serious pulmonary embolism, not requiring intensive care (thrombectomy or fibrinolysis not considered).
  • sPESI score ≥ 1 [or = 0 with elevated troponin or presence of markers of VD dysfunction, or = 0 with need for hospitalization due to comorbidities unrelated to PE (social isolation, comprehension disorders, intercurrent infection, chronic renal failure, advanced cancer...)
  • Patients with no contraindications to chair lift testing (no O2 at the time of testing).
  • Effective anticoagulation for at least 1 hour.

Exclusion criteria

Exclusion Criteria:

  • sPESI score = 0 with outpatient referral.
  • Diagnostic confirmation of Pulmonia Embolism by thoracic angioscan or scintigraphy more than 24h after suspicion of diagnosis.
  • Hospitalization > 24h after introduction of anticoagulation, with subsequent confirmation by scintigraphy.
  • Any sign of serious Pulmonia Embolism, requiring hospitalization in an intensive care unit.
  • Asymptomatic Pulmonia Embolism discovered by chance
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    chair lift test

    Other: chair lift test

Interventions

  • Otherchair lift test

    repetitions of the sit-stand position at a self-timed speed (safe and comfortable) as many times as possible for 1 minute

05

What researchers measure

Primary outcomes

  1. sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the one-minute chair rise test in comparison with the gold standard refined by the use of cardiac biomarkers and right ventricular dysfunction

    Time frame: 1 day

Secondary outcomes

  1. Troponin measurement

    Time frame: 1 day

  2. Presence or absence of post-pulmonary embolism dyspnea

    Time frame: 6 months

  3. Overall survival

    Time frame: 6 months

06

Study locations

1 of 1 sites recruiting
  • Chu Rouen
    Rouen, 76031, France
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06166329
Lead sponsor
University Hospital, Rouen
Responsible party
Sponsor
First posted
Dec 12, 2023
Start date
Feb 9, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Delphine SIMON, MD
Contact
delphine.simon@chu-rouen.fr
2 32 88 73 97 ext. +33
Armelle GUIDOTTI
Contact
armelle.guidotti@chu-rouen.fr
232888265 ext. +33
Delphine SIMON, MD
principal investigator · University Hospital, Rouen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pulmonary Embolism→

Other studies from this sponsor

University Hospital, Rouen

Start the discussion